Advertisement

International Journal of Hematology

, Volume 77, Issue 4, pp 371–375 | Cite as

Size and Composition of T-Cell Receptor δ (TCRD) Junctional Sequences Are Not Predictive of the Sensitivity of Clonospecific Oligonucleotides Designed for Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia

  • Taku Seriu
  • Yvonne Stark
  • Dorothee Erz
  • Claus R. Bartram
Article
  • 26 Downloads

Abstract

We characterized 168 junctional regions of T-cell receptor δ (TCRD) rearrangements from 116 children with acute lymphoblastic leukemia (ALL) (101 with precursor B-cell ALL, 15 with T-cell ALL). Application of 101 allele-specific oligonucleotide (ASO) probes representing 85 Vδ2Dδ3, 10 Dδ2Dδ3, 3 Vδ1Jδ1, 1 Vδ3Jδ1, and 2 Dδ2Jδ1 junctions for the detection of minimal residual disease (MRD) revealed detection levels of 10-4 to 10-6 leukemia cells in the vast majority of cases (93 of 101). Of interest was that neither the N,D, P (nontemplated, diversity, palindromic) content and length of the junctional regions nor the number of nucleotides deleted from the flanking V, D, or J (variable, diversity, joining) elements correlated with the sensitivity of ASO probes. These data indicated that in ALL TCRD rearrangements can serve as suitable tools for the detection of MRD irrespective of the specific composition of the junctional region.

Key words

TCRD rearrangement Minimal residual disease Acute lymphoblastic leukemia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cave H, van der Werfften Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia.N Engl J Med. 1998;339:591–598.CrossRefPubMedGoogle Scholar
  2. 2.
    van Dongen JJM, Seriu T, Panzer-Grümayer ER, et al. Prognostic value on minimal residual disease in acute lymphoblastic leukaemia in childhood.Lancet. 1998;352:1731–1738.CrossRefPubMedGoogle Scholar
  3. 3.
    Willemse MJ, Seriu T, Hettinger K, et al. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL.Blood. 2002;99:4386–4393.CrossRefPubMedGoogle Scholar
  4. 4.
    Pongers-Willemse MJ, Seriu T, Stolz F, et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets.Leukemia. 1999;13:110–118.CrossRefPubMedGoogle Scholar
  5. 5.
    Pongers-Willemse MJ, Verhagen OJHM, Tibbe GJM, et al. Realtime quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.Leukemia. 1998;12:2006–2014.CrossRefPubMedGoogle Scholar
  6. 6.
    Nakao M, Janssen JWG, Flohr T, Bartram CR. Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology.Cancer Res. 2000;60:3281–3289.PubMedGoogle Scholar
  7. 7.
    Guidal C, Vilmer E, Grandchamp B, et al. A competitive PCRbased method usingTCRD, TCRG andIGH rearrangements for rapid detection of patients with high levels of minimal residual disease in acute lymphoblastic leukemia.Leukemia. 2002;16:762–764.CrossRefPubMedGoogle Scholar
  8. 8.
    Breit TM, Wolvers-Tettero IL, Beishuizen A, Verhoven MAJ, van Wering ER, van Dongen JJM. Southern blot patterns, frequencies and junctional diversity of T-cell receptor-δ gene rearrangements in acute lymphoblastic leukemia.Blood. 1993;82:3063–3074.PubMedGoogle Scholar
  9. 9.
    Szczepanski T, Beishuizen A, Pongers-Willemse MJ, et al. Crosslineage T cell receptor gene rearrangements occur in more than ninety percent of childhood precursor-B acute lymphoblastic leukemias: alternative PCR targets for detection of minimal residual disease.Leukemia. 1999;13:196–205.CrossRefPubMedGoogle Scholar
  10. 10.
    Breit TM, Wolvers-Tettero ILM, Hählen K, van Wering ER, van Dongen JJM. Extensive junctional diversity of γ δ T-cell receptors expressed by T-cell acute lymphoblastic leukemia: implications for the detection of minimal residual disease.Leukemia. 1991;5:1076–1086.PubMedGoogle Scholar
  11. 11.
    van der Does-van den Berg A, Bartram CR, Basso G, et al. Minimal requirements for the diagnosis, classification and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the “BFM Family” cooperative group.Med Pediatr Oncol. 1992;20:497–505.CrossRefGoogle Scholar
  12. 12.
    Yokota S, Hansen-Hagge TE, Ludwig WD, et al. Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients.Blood. 1991;77:331–339.PubMedGoogle Scholar
  13. 13.
    Seriu T, Hansen-Hagge TE, Erz DHR, Bartram CR. Improved detection of minimal residual leukemia through modifications of polymerase chain reaction analyses based on clonospecific T cell receptor junctions.Leukemia. 1995;9:316–320.PubMedGoogle Scholar
  14. 14.
    Seriu T, Erz D, Stark Y, Bartram CR. T-cell receptor Dδ2Dδ3 rearrangement: a suitable allele-specific marker for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.Leukemia. 1997;11:759–761.CrossRefPubMedGoogle Scholar
  15. 15.
    Hansen-Hagge TE, Mahotka C, Panzer-Grümayer RE, et al. Alternative splicing restricts translation of rearrangements at the T-cell receptor δ/ α locus.Blood. 1995;85:1888–1896.PubMedGoogle Scholar
  16. 16.
    Lewis SM, Hesse JE. Cutting and closing without recombination in V(D)J joining.EMBO J. 1991;10:3631–3639.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2003

Authors and Affiliations

  • Taku Seriu
    • 1
  • Yvonne Stark
    • 1
  • Dorothee Erz
    • 1
  • Claus R. Bartram
    • 1
  1. 1.Institute of Human GeneticsUniversity of HeidelbergHeidelbergGermany

Personalised recommendations